Advent International, the global private equity firm, today announced that it has agreed to make a strategic investment in Laboratorio LKM S.A. (LKM), a leading specialty pharmaceutical manufacturer in Argentina. The equity investment will support LKM’s efforts to consolidate its position in Argentina and further expand into other Latin American markets. Under the agreement, Advent will purchase a majority ownership interest from LKM’s founding Kampel family, and, together with the Kampel family, will make a capital injection of approximately Ar$50 million to support the company’s expansion plans, including a project to build a plant to export products to European markets. The value of the transaction and other financial terms were not disclosed. The investment is subject to customary closing conditions.
